BDO Midlands provided financial and tax due diligence to Clinigen and the group’s debt funders in connection with its £150m acquisition of Quantum Pharma.
Based in Burton-on-Trent, AIM-listed Clinigen is a global pharmaceutical products and services group with a current market capitalisation of c£1.4bn. Durham-based Quantum Pharma is engaged in the provision of unlicensed presentations of licenced products on a named patient basis.
The acquisition is expected to enhance Clinigen’s position as the global leader in ethical access to unlicensed medicines and accelerate the group’s global “Unlicenced to Licensed” (“UL2L”) strategy.
"Again we were delighted with the work undertaken by BDO on our behalf in relation to the acquisition of Quantum Pharma. They have been our preferred supplier of Transaction Services since IPO and have a good understanding of our business model and apply a flexible, pragmatic, and solutions driven approach. They understand the importance of hitting deadlines in order to facilitate a smooth process and we look forward to working with them on future projects."
Martin Abell, Chief Financial Officer